Assenagon Asset Management S.A. Takes Position in West Pharmaceutical Services Inc. (WST)

Assenagon Asset Management S.A. bought a new stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 35,165 shares of the medical instruments supplier’s stock, valued at approximately $4,342,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Burt Wealth Advisors boosted its stake in shares of West Pharmaceutical Services by 113.7% during the 2nd quarter. Burt Wealth Advisors now owns 4,128 shares of the medical instruments supplier’s stock valued at $410,000 after purchasing an additional 2,196 shares in the last quarter. Riverbridge Partners LLC boosted its stake in shares of West Pharmaceutical Services by 37.8% during the 3rd quarter. Riverbridge Partners LLC now owns 647,980 shares of the medical instruments supplier’s stock valued at $80,006,000 after purchasing an additional 177,637 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of West Pharmaceutical Services by 0.7% during the 2nd quarter. Macquarie Group Ltd. now owns 107,213 shares of the medical instruments supplier’s stock valued at $10,645,000 after purchasing an additional 786 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of West Pharmaceutical Services by 7.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 345,633 shares of the medical instruments supplier’s stock valued at $34,318,000 after purchasing an additional 23,700 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of West Pharmaceutical Services by 27.1% during the 2nd quarter. Janus Henderson Group PLC now owns 875,723 shares of the medical instruments supplier’s stock valued at $86,951,000 after purchasing an additional 186,752 shares in the last quarter. 93.64% of the stock is currently owned by hedge funds and other institutional investors.

In related news, SVP Karen Flynn sold 20,458 shares of the business’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total transaction of $2,377,833.34. Following the sale, the senior vice president now owns 31,051 shares of the company’s stock, valued at $3,609,057.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.90% of the company’s stock.

NYSE:WST opened at $106.16 on Friday. West Pharmaceutical Services Inc. has a one year low of $82.74 and a one year high of $125.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.94 and a current ratio of 2.94. The stock has a market cap of $7.86 billion, a P/E ratio of 38.19, a price-to-earnings-growth ratio of 4.01 and a beta of 1.19.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.76 EPS for the quarter, topping the consensus estimate of $0.70 by $0.06. West Pharmaceutical Services had a net margin of 9.06% and a return on equity of 15.78%. The business had revenue of $431.70 million for the quarter, compared to analyst estimates of $427.55 million. Research analysts anticipate that West Pharmaceutical Services Inc. will post 2.8 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. ValuEngine raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

See Also: Understanding Market Liquidity

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply